SCHEMBL24087920

SCHEMBL24087920

N#Cc1c(Cc2cccs2)nc(SCC(=O)O)[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.55
▸ NPSR1 Q6W5P4 7/20 0.55
▸ MEN1 O00255 6/20 0.55
▸ PRNP P04156 6/20 0.55
▸ RXFP1 Q9HBX9 6/20 0.55
▸ HPGD P15428 5/20 0.53
▸ MAPT P10636 4/20 0.53
▸ PSMD14 O00487 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ KDM4E B2RXH2 3/20 0.50
▸ THRB P10828 1/20 0.50
▸ APEX1 P27695 1/20 0.50
▸ MC4R P32245 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ DUSP3 P51452 1/20 0.50
▸ PTPN5 P54829 1/20 0.50
▸ PTPN11 Q06124 1/20 0.50
▸ ACMSD Q8TDX5 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26847479 0.91 NPSR1 (0.68) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL24087922 0.89 RXFP1 (0.56) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL26847482 0.89 RXFP1 (0.61) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL24087919 0.85 RXFP1 (0.54) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL23853755 0.83 ACMSD (0.53) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL23850319 0.81 KMT2A (0.82) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL26847480 0.80 PRNP (0.46) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL24087944 0.80 ACMSD (0.51) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL24087917 0.79 ACMSD (0.45) KMT2ANPSR1MEN1PRNPRXFP1
SCHEMBL24088150 0.79 PRNP (0.44) KMT2ANPSR1MEN1PRNPRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2023-11-30 — — US disclosed
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S R L (IT) 2021-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 KMT2A 1353/4885NPSR1 2669/4885MEN1 2572/4885
US-20210379069-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 KMT2A 1353/4885NPSR1 2669/4885MEN1 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback